Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

basic toxicokinetics
Type of information:
other: predictions from Basic Data set
Adequacy of study:
weight of evidence
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: A qualitative assessment of the toxicokinetics of the substance has been performed, based upon its physical properties and the results of toxicological studies.

Data source

Materials and methods

Test guideline
according to guideline
other: Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7c: Endpoint specific guidance Version 2.0 November 2014
GLP compliance:

Test material

Constituent 1
Chemical structure
Reference substance name:
[5-acetyl-2-(acetyloxy)phenyl]methyl acetate
EC Number:
Cas Number:
Molecular formula:
[5-acetyl-2-(acetyloxy)phenyl]methyl acetate

Results and discussion

Metabolite characterisation studies

Metabolites identified:
not specified

Bioaccessibility (or Bioavailability)

Bioaccessibility (or Bioavailability) testing results:
key physical properties:
Molecular weight: 250.2
Water solubility: 3.41 g/L
Partition co-efficient log Pow: 1.08
Particle size distribution: 99.9% (>2000 µm), 0.1% (> 173.815 µm)
Dissociation constant: not determined
pH (10% suspension ): 4.0-4.1
Hydrolysis: not determined
Structural alerts- no readily ionisable groups present

Any other information on results incl. tables

acute oral toxicity:: discriminating dose 500mg/kg bw

Abnormalities noted at necropsy of animals that died during the study were haemorrhagic or abnormally red lungs, dark liver or patchy pallor of the liver, dark kidneys.

28 day repeat dose oral toxicity (OECD422: No toxicologically significant effects on feetility, reproductive performance or pup development were noted upto the maximum dose tested (100mg/kg bw/day).

Reproductive Toxicity Screen (OECD422):

No toxicologically significant systemic effects were noted upto the maximum dose tested (100mg/kg bw/day)

skin exposure: irritant effects were noted in in vivo studies with guinea pigs and also the acute dermal toxicity study in rats. While the effects observed were not sufficient to meet the classificaiton criteria for irritation, these results are indicative of the potential for the substance to penetrate the stratum corneum.

eye exposure: when tested in the BCOP test system the substance is considered to induce severe eye damage, however the substance does not significantly increase corneal permeability.

Applicant's summary and conclusion

Interpretation of results (migrated information): low bioaccumulation potential based on study results
oral: evidence presented by the acute oral toxicity study indicates that the substance is absorbed following administration in arachis oil with systemic effects noted in the lungs, liver and kidney following exposure to 2000 mg/kg. No toxicologically significant effects were noted following exposure of rats in a subacute study at a maximum concentraiton of 100mg/kg bw/day, indicative of a low potential for bioaccumulation. Additionally no toxicologically significant effects were observed on reproductive or developmental parameters in the expsoed animals.
The water solubility, partition coefficient and molecular mass all indicate that this substance will be bioavailable via the oral route.

Inhalation: The particle size distribution indicates that there is limited potential for exposure by this route.

Dermal absorption: Results from in vivo irritation and dermal toxicity studies, in addition to the physical parameters of molecular weight and log Pow, indicate that the substance can penetrate the stratum corneum and is systemically available from dermal exposure.

Metabolism: There is no evidence from the 28 day study to indicate that the substance is undergoing extensive hepatic metabolism (lack of adaptive hepatic hypertrophy). No specific metabolism studies have been undertaken however the reduction of genotoxic activity of the substance by S9 fraction in the in vitro genotoxicity and mutagenicity assays conducted would indicate that hepatic metabolism of the substance is likely.

Excretion: There is limited evidence from the oral toxicity studies conducted ( dark kidneys in acute studies and non-significant increases in creatinine in repeat dose studies) that the substance may interact with the kidneys.
Executive summary:

Based upon the results of acute toxicity testing and the physical properties of the substance, it can be predicted that absorption and distribution can be expected by the oral and dermal routes. Uptake is unlikely by the inhalation route, given the particle size distribution of the substance.

There is little to no evidence of the metabolic or excretion profile of the substance however the lack of systemic effects observed in the repeat dose study is indicative of a metabolic/excretion pathway.